Emisphere Technologies, Inc., a biopharmaceutical company, specializes in the oral delivery of therapeutic macromolecules and other compounds. It develops products using eligen, a proprietary oral drug delivery technology, based on the use of synthetic chemical compounds, known as EMISPHERE delivery agents. These delivery agents transport therapeutic macromolecules and small molecules, which include proteins, peptides, carbohydrates, polar organics, and other compounds, across biological membranes. The company’s development stage products include Oral Salmon Calcitonin, which is in Phase II clinical trials for the treatment of Osteoporosis and Osteoarthritis; Oral Recombinant Parathyroid Hormone, which is in Phase I clinical trials, for the treatment of Osteoporosis; partner proprietary small molecule compounds, which are in Phase I clinical trials for use in the treatment of bone-related diseases; Oral Recombinant Human Growth Hormone which is in Phase I clinical trials, for the treatment of growth disorders; and Oral Insulin for the treatment of diabetes. Emisphere Technologies’ preclinical stage products consist of Oral Glucagon-Like Peptides for the treatment of diabetes; and Acyclovir, an antiviral compound. It has a collaboration agreement with Novartis Pharma AG; and license agreements with Hoffmann-La Roche, Inc. and F. Hoffmann-La Roche, LTD., as well as with Genta Incorporated and Emisphere Technologies, Inc. The company was founded in 1985. It was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies is based in Tarrytown, New York.
Gallery View 4: (Full Sto, MACD, Aroon8)